Articles

  1. Curia R&D Pipeline Overview 2/18/2026

    This pipeline outlines a sequence of late‑stage and emerging therapeutics projected to launch between 2024 and 2031, spanning immunology, neurology, psychiatry, rare disease, oncology, and inflammatory disorders.

  2. A Patented Process For Intermediates Useful For Upadacitinib 2/18/2026

    Discover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.

  3. Redefining OSD Development Through Foresight And Innovation 2/12/2026

    From early formulation challenges to scale-up and commercial readiness, proactive planning and integrated capabilities help teams anticipate risks, accelerate decision-making, and maintain momentum across development.

  4. FIH: Reach Milestones Sooner With A Technology-Driven Approach 2/12/2026

    Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

  5. Development Of A Non-Standard Protein Therapeutic 2/4/2026

    Discover how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.

  6. Put Your Oligo Synthesis In Good Hands 1/27/2026

    Explore how smart column design supports consistent, high‑yield oligonucleotide synthesis, which formats fit development, and how optimized features help improve efficiency and safety.

  7. Selecting A CDMO For Custom Activated PEGs 1/27/2026

    Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

  8. State-Of-The-Art Drug Product Manufacturing Capabilities 1/26/2026

    Integrated development, analytical, and manufacturing capabilities streamline complex formulations and clinical supply, while flexible, advanced services keep teams moving challenging products forward.

  9. From Sequence To Clinic: Faster Decisions Through In Silico Insights 1/21/2026

    In‑silico modeling enables early prediction of molecule stability, formulatability, and risks, reducing lab work, guiding candidate selection, and supporting efficient drug‑product development from sequence to clinic.

  10. Advancing Lyophilization Through Formulation, Process Development 1/21/2026

    Lyophilization development and modeling improve stability, streamline freeze‑drying cycles, reduce risks, and support efficient advancement of sensitive formulations.